Single User License
INR 134840
Site License
INR 269680
Corporate User License
INR 404520

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Chemotherapy Induced Anemia-Pipeline Review, H1 2015

Chemotherapy Induced Anemia-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Chemotherapy Induced Anemia-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Chemotherapy Induced Anemia-Pipeline Review, H1 2015', provides an overview of the Chemotherapy Induced Anemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chemotherapy Induced Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Anemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Anemia

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Chemotherapy Induced Anemia and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Chemotherapy Induced Anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Chemotherapy Induced Anemia pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Anemia

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Anemia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Chemotherapy Induced Anemia Overview 7

Therapeutics Development 8

Pipeline Products for Chemotherapy Induced Anemia-Overview 8

Pipeline Products for Chemotherapy Induced Anemia-Comparative Analysis 9

Chemotherapy Induced Anemia-Therapeutics under Development by Companies 10

Chemotherapy Induced Anemia-Pipeline Products Glance 11

Late Stage Products 11

Clinical Stage Products 12

Early Stage Products 13

Chemotherapy Induced Anemia-Products under Development by Companies 14

Chemotherapy Induced Anemia-Companies Involved in Therapeutics Development 15

3SBio Inc. 15

Aprogen, Inc. 16

Avesthagen Limited 17

Panacea Biotec Limited 18

Pieris AG 19

ProMetic Life Sciences Inc. 20

Sandoz International GmbH 21

Therapure Biopharma Inc. 22

Tolero Pharmaceuticals, Inc. 23

Chemotherapy Induced Anemia-Therapeutics Assessment 24

Assessment by Monotherapy Products 24

Assessment by Target 25

Assessment by Mechanism of Action 27

Assessment by Route of Administration 29

Assessment by Molecule Type 31

Drug Profiles 33

darbepoetin alfa-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

darbepoetin alfa-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

darbepoetin alfa-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

epoetin alfa (recombinant)-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

NuPIAO-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

PBI-1402-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

PBI-4494-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

PRS-080-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

TBI-304-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

TP-0413-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

TXA-302-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

Chemotherapy Induced Anemia-Recent Pipeline Updates 47

Chemotherapy Induced Anemia-Dormant Projects 49

Chemotherapy Induced Anemia-Discontinued Products 50

Chemotherapy Induced Anemia-Product Development Milestones 51

Featured News & Press Releases 51

Sep 30, 2010: Safety study for subcutaneous epoetin alfa biosimilar Binocrit/Epoetin alfa Hexal/Abseamed suspended 51

Dec 01, 2008: International presentation of clinical safety and efficacy data for Binocrit, the world's first complex biosimilar 51

Jan 07, 2008: Sandoz and Gambro form strategic alliance 52

Aug 31, 2007: European Commission approves Sandoz's epoetin alfa Binocrit 52

Appendix 53

Methodology 53

Coverage 53

Secondary Research 53

Primary Research 53

Expert Panel Validation 53

Contact Us 53

Disclaimer 54

List of Tables

Number of Products under Development for Chemotherapy Induced Anemia, H1 2015 8

Number of Products under Development for Chemotherapy Induced Anemia-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Comparative Analysis by Late Stage Development, H1 2015 11

Comparative Analysis by Clinical Stage Development, H1 2015 12

Comparative Analysis by Early Stage Development, H1 2015 13

Products under Development by Companies, H1 2015 14

Chemotherapy Induced Anemia-Pipeline by 3SBio Inc., H1 2015 15

Chemotherapy Induced Anemia-Pipeline by Aprogen, Inc., H1 2015 16

Chemotherapy Induced Anemia-Pipeline by Avesthagen Limited, H1 2015 17

Chemotherapy Induced Anemia-Pipeline by Panacea Biotec Limited, H1 2015 18

Chemotherapy Induced Anemia-Pipeline by Pieris AG, H1 2015 19

Chemotherapy Induced Anemia-Pipeline by ProMetic Life Sciences Inc., H1 2015 20

Chemotherapy Induced Anemia-Pipeline by Sandoz International GmbH, H1 2015 21

Chemotherapy Induced Anemia-Pipeline by Therapure Biopharma Inc., H1 2015 22

Chemotherapy Induced Anemia-Pipeline by Tolero Pharmaceuticals, Inc., H1 2015 23

Assessment by Monotherapy Products, H1 2015 24

Number of Products by Stage and Target, H1 2015 26

Number of Products by Stage and Mechanism of Action, H1 2015 28

Number of Products by Stage and Route of Administration, H1 2015 30

Number of Products by Stage and Molecule Type, H1 2015 32

Chemotherapy Induced Anemia Therapeutics-Recent Pipeline Updates, H1 2015 47

Chemotherapy Induced Anemia-Dormant Projects, H1 2015 49

Chemotherapy Induced Anemia-Discontinued Products, H1 2015 50

List of Figures

Number of Products under Development for Chemotherapy Induced Anemia, H1 2015 8

Number of Products under Development for Chemotherapy Induced Anemia-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Comparative Analysis by Clinical Stage Development, H1 2015 12

Comparative Analysis by Early Stage Products, H1 2015 13

Assessment by Monotherapy Products, H1 2015 24

Number of Products by Top 10 Targets, H1 2015 25

Number of Products by Stage and Top 10 Targets, H1 2015 26

Number of Products by Top 10 Mechanism of Actions, H1 2015 27

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 28

Number of Products by Top 10 Routes of Administration, H1 2015 29

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 30

Number of Products by Top 10 Molecule Types, H1 2015 31

Number of Products by Stage and Top 10 Molecule Types, H1 2015 32

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

3SBio Inc.

Aprogen, Inc.

Avesthagen Limited

Panacea Biotec Limited

Pieris AG

ProMetic Life Sciences Inc.

Sandoz International GmbH

Therapure Biopharma Inc.

Tolero Pharmaceuticals, Inc.

Chemotherapy Induced Anemia Therapeutic Products under Development, Key Players in Chemotherapy Induced Anemia Therapeutics, Chemotherapy Induced Anemia Pipeline Overview, Chemotherapy Induced Anemia Pipeline, Chemotherapy Induced Anemia Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com